Crysvita FDA Approval History
FDA Approved: Yes (First approved April 17, 2018)
Brand name: Crysvita
Generic name: burosumab-twza
Dosage form: Injection
Company: Ultragenyx Pharmaceutical Inc.
Treatment for: X-Linked Hypophosphatemia; Tumor-Induced Osteomalacia
Crysvita (burosumab-twza) is a fibroblast growth factor 23 (FGF23) blocking antibody for the treatment of x-linked hypophosphatemia (XLH) and FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO).
Development Timeline for Crysvita
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.